Clinical Trial Update: Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety of 68Ga-DOTA-tyr3-Octreotide PET in diagnosing solid tumors has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumors
• Medulloblastoma
• Neuroblastoma
• Neuroendocrine Tumors

Drugs mentioned

• 68Ga-DOTA-tyr3-Octreotide PET (68Ga-DOTA-tyr3-Octreotide)

Snippet

Sponsor: Sue O'Dorisio | Conditions: Neuroendocrine Tumors, Carcinoid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-02-02